Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
IPCALAB.NS
Strong BuyPremium GrowerIpca Laboratories Limited · Healthcare · India · $5.3B · Avg Vol: $11M/d
91
StockRankGet insider-trade alerts
Q
82
V
29
M
82
P/E (TTM)
38.1x
ROE
14.2%
D/E
0.1x
Dividend %
0.3%
COMPANY DESCRIPTION
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 62.1B | 76.2B | 88.5B | 95.6B | 15.5% | 101.6B | 109.0B | 121.6B | 12.8% |
| EPS (INR) | 18.58 | 21.57 | 29.08 | 44.98 | 34.3% | 51.72 | 57.47 | 67.37 | 22.4% |
| Shares | 253.7M | 253.7M | 253.7M | 253.7M | 0.0% | 253.7M | — | — | — |
| Debt | 14.8B | 14.4B | 13.6B | 8.1B | -18.3% | 8.1B | — | — | — |
| Equity | 58.4B | 63.3B | 69.5B | 80.6B | 11.3% | — | — | — | — |
| Op CF | 8.1B | 9.4B | 13.2B | 11.4B | 12.3% | 11.5B | — | — | — |
| Inv CF | -7.3B | -12.9B | -8.7B | -2.5B | — | — | — | — | — |
| Fin CF | 5.1B | -5.5B | -2.8B | -7.5B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+12.0%
SMA 50SMA 200
Close
$20.58
RSI (14)
69.2
52W High
$20.97
From 52W High
1.0%
SCORE BREAKDOWN
Quality
82
ROIC
18.7%89.1
ROE
14.2%80.4
GP/Assets
55.4%89.3
Op. Margin
20.0%83.2
FCF/Assets
9.2%85.2
Piotroski
999.1
Int. Cover
27.2x74.0
D/E Ratio
0.08x64.3
Current Ratio
2.76x51.7
Value
29
P/E (TTM)
38.1x30.1
EV/EBITDA
22.6x29.9
P/FCF
43.8x33.1
P/B
6.2x21.7
P/S
4.9x42.1
Div Yield
0.3%9.1
Momentum
82
52W High %
98%98.5
RS 6M
33%86.3
SMA 50/200
1.16x83.8
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+36%46.0
Q Growth
72%80.2
FUNDAMENTALS
Market Cap
$5.3B
P/E (Forward)
27.9x
Gross Margin
67.7%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IPCALAB.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IPCALAB.NS | Ipca Laboratories Limited(you) | $5.3B | 91 | Strong Buy |
| GLAND.NS | Gland Pharma Limited | $5.1B | 88 | Strong Buy |
| GLENMARK.NS | Glenmark Pharmaceuticals Limited | $7.4B | 94 | Strong Buy |
| LUPIN.NS | Lupin Limited | $10.2B | 91 | Strong Buy |
| AUROPHARMA.NS | Aurobindo Pharma Limited | $10.3B | 91 | Strong Buy |
| ABBOTINDIA.NS | Abbott India Limited | $5.7B | 79 | Buy |
| AJANTPHARM.NS | Ajanta Pharma Limited | $4.7B | 79 | Buy |
| EMCURE.NS | Emcure Pharmaceuticals Limited | $3.9B | 81 | Strong Buy |
| GRANULES.NS | Granules India Limited | $2.3B | 87 | Strong Buy |
| ALIVUS.NS | Alivus Life Sciences Limited | $1.8B | 91 | Strong Buy |
Peer medians: ROE 11.8% · P/E 42.8x · Gross margin 59.4%